Pages that link to "Q30712004"
Jump to navigation
Jump to search
The following pages link to The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. (Q30712004):
Displaying 26 items.
- Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (Q28252209) (← links)
- Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders (Q34391577) (← links)
- A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy (Q35145905) (← links)
- The promise and reality of pharmacogenetics in psychiatry (Q35226451) (← links)
- Enhanced mitochondrial superoxide scavenging does not improve muscle insulin action in the high fat-fed mouse (Q35625287) (← links)
- Clinical implications of pharmacogenomics for tardive dyskinesia (Q35712215) (← links)
- Meta-Analyses of Manganese Superoxide Dismutase Activity, Gene Ala-9Val Polymorphism, and the Risk of Schizophrenia (Q36194852) (← links)
- Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation (Q36460687) (← links)
- Association between pepsinogen C gene polymorphism and genetic predisposition to gastric cancer (Q36506379) (← links)
- MnSOD and GPx1 polymorphism relationship with coronary heart disease risk and severity (Q36790505) (← links)
- Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research (Q36840610) (← links)
- Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics (Q37264543) (← links)
- Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls (Q37699340) (← links)
- Pharmacogenetics of response to antipsychotics in patients with schizophrenia (Q37952823) (← links)
- Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions (Q40136199) (← links)
- Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia (Q42517435) (← links)
- Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia (Q43205100) (← links)
- Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. (Q46218017) (← links)
- Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia (Q47787904) (← links)
- Polymorphism in the manganese superoxide dismutase gene (Q48589651) (← links)
- Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia. (Q50602362) (← links)
- The Promise and Reality of Pharmacogenetics in Psychiatry (Q51846528) (← links)
- Polymorphic mutations of the Mn-SOD gene in intact human lymphocytes and oral squamous cell carcinoma cell lines (Q73233249) (← links)
- Manganese superoxide dismutase polymorphism in chronic pelvic pain syndrome patients (Q79923436) (← links)
- Manganese superoxide dismutase (Mn-SOD) gene polymorphisms in urolithiasis (Q80606215) (← links)
- No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia (Q83995184) (← links)